{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:36:56Z","timestamp":1783528616658,"version":"3.55.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment approaches have improved the outlook for many individuals with these disorders; however, with these advances come new questions. Given the long-term survival of patients with FL, drugs with favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current treatment modalities. It often runs an indolent course with multiple relapses and progressively shorter intervals of remission. The identification of new targets and development of novel targeted therapies is imperative to exploit the biology of FL while inherently preventing relapse and prolonging survival. This review summarizes the growing body of knowledge regarding novel therapeutic targets, enabling the concept of individualized targeted therapy for the treatment of FL.<\/jats:p>","DOI":"10.1186\/1756-8722-2-50","type":"journal-article","created":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T19:16:15Z","timestamp":1261595775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["New targets for the treatment of follicular lymphoma"],"prefix":"10.1186","volume":"2","author":[{"given":"Nishant","family":"Tageja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Padheye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Dandawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi M","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,23]]},"reference":[{"key":"77_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E: Cancer Statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322\/CA.2007.0010.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"77_CR2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998, 16 (8): 2780-95.","journal-title":"J Clin Oncol"},{"issue":"12","key":"77_CR3","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999, 17 (12): 3835-49.","journal-title":"J Clin Oncol"},{"key":"77_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Can Inst. 2007, 99: 706-14. 10.1093\/jnci\/djk152.","journal-title":"J Natl Can Inst"},{"key":"77_CR5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998, 16: 2825-33.","journal-title":"J Clin Oncol"},{"issue":"8","key":"77_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/sj.leu.2403801","volume":"19","author":"IS Lossos","year":"2005","unstructured":"Lossos IS: Higher-grade transformation of follicular lymphoma -- a continuous enigma. Leukemia. 2005, 19 (8): 1331-3. 10.1038\/sj.leu.2403801.","journal-title":"Leukemia"},{"key":"77_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0074-7696(08)62312-8","volume":"68","author":"AH Wyllie","year":"1980","unstructured":"Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol. 1980, 68: 251-10.1016\/S0074-7696(08)62312-8.","journal-title":"Int Rev Cytol"},{"key":"77_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","volume":"281","author":"A Ashkenazi","year":"1998","unstructured":"Ashkenazi A, Dixit VM: Death Receptors- Signaling and Modulation. Science. 1998, 281: 1305-10.1126\/science.281.5381.1305.","journal-title":"Science"},{"key":"77_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1042\/BST0290696","volume":"29","author":"EM Creagh","year":"2001","unstructured":"Creagh EM, Martin SJ: Capases: cellular demolition experts. Biochem Soc Trans. 2001, 29: 696-10.1042\/BST0290696.","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"77_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0092-8674(00)80434-1","volume":"91","author":"P Li","year":"1997","unstructured":"Li P, Nijhawan D, Budihardjo I: Cytochrome c and dATP-dependent formation of Apaf-1\/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997, 91 (4): 479-89. 10.1016\/S0092-8674(00)80434-1.","journal-title":"Cell"},{"key":"77_CR11","first-page":"13","volume":"615","author":"GS Salvesen","year":"2008","unstructured":"Salvesen GS, Riedl SJ: Caspase Mechanisms. Adv Exp Med Biol. 2008, 615: 13-23. full_text.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"77_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/0012-1606(77)90158-0","volume":"56","author":"JE Sulston","year":"1977","unstructured":"Sulston JE, Horvitz HR: Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol. 1977, 56 (1): 110-56. 10.1016\/0012-1606(77)90158-0.","journal-title":"Dev Biol"},{"issue":"6369","key":"77_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/356494a0","volume":"356","author":"MO Hengartner","year":"1992","unstructured":"Hengartner MO, Ellis RE, Horvitz HR: Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature. 1992, 356 (6369): 494-9. 10.1038\/356494a0.","journal-title":"Nature"},{"issue":"6189","key":"77_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988, 335 (6189): 440-21. 10.1038\/335440a0.","journal-title":"Nature"},{"issue":"9","key":"77_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002, 2 (9): 647-56. 10.1038\/nrc883. Review","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"77_CR16","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1002\/j.1460-2075.1995.tb00246.x","volume":"14","author":"T Chittenden","year":"1995","unstructured":"Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ: A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 1995, 14 (22): 5589-96.","journal-title":"EMBO J"},{"issue":"3","key":"77_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002, 2 (3): 183-92. 10.1016\/S1535-6108(02)00127-7.","journal-title":"Cancer Cell"},{"issue":"8","key":"77_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0962-8924(98)01321-X","volume":"8","author":"A Kelekar","year":"1998","unstructured":"Kelekar A, Thompson CB: Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8 (8): 324-30. 10.1016\/S0962-8924(98)01321-X.","journal-title":"Trends Cell Biol"},{"issue":"4","key":"77_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/emboj\/17.4.1029","volume":"17","author":"DC Huang","year":"1998","unstructured":"Huang DC, Adams JM, Cory S: The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998, 17 (4): 1029-39. 10.1093\/emboj\/17.4.1029.","journal-title":"EMBO J"},{"issue":"17","key":"77_CR20","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1073\/pnas.92.17.7834","volume":"92","author":"TW Sedlak","year":"1995","unstructured":"Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA. 1995, 92 (17): 7834-8. 10.1073\/pnas.92.17.7834.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"77_CR21","first-page":"327","volume":"4","author":"SJ Korsmeyer","year":"1993","unstructured":"Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2\/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993, 4 (6): 327-32.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"77_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0092-8674(95)90411-5","volume":"80","author":"E Yang","year":"1995","unstructured":"Yang E, Zha J, Jockel J: BAD, a heterodimeric partner for Bcl-XL and Bcl-2, displaces BAX and promotes cell death. Cell. 1995, 80 (2): 285-91. 10.1016\/0092-8674(95)90411-5.","journal-title":"Cell"},{"issue":"39","key":"77_CR23","doi-asserted-by":"publisher","first-page":"24101","DOI":"10.1074\/jbc.272.39.24101","volume":"272","author":"J Zha","year":"1997","unstructured":"Zha J, Harada H, Osipov K: BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem. 1997, 272 (39): 24101-4. 10.1074\/jbc.272.39.24101.","journal-title":"J Biol Chem"},{"issue":"2","key":"77_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1097-2765(02)00442-2","volume":"9","author":"D Acehan","year":"2002","unstructured":"Acehan D, Jiang X, Morgan DG, Heuser JE: Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell. 2002, 9 (2): 423-432. 10.1016\/S1097-2765(02)00442-2.","journal-title":"Mol Cell"},{"issue":"17","key":"77_CR25","doi-asserted-by":"publisher","first-page":"11549","DOI":"10.1074\/jbc.274.17.11549","volume":"274","author":"H Zou","year":"1999","unstructured":"Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274 (17): 11549-56. 10.1074\/jbc.274.17.11549.","journal-title":"J Biol Chem"},{"issue":"4","key":"77_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.cdd.4400659","volume":"7","author":"ME Fitch","year":"2000","unstructured":"Fitch ME, Chang CM, Parslow TG: The BH3 domain is required for caspase-independent cell death induced by Bax and oligomycin. Cell Death Differ. 2000, 7 (4): 338-49. 10.1038\/sj.cdd.4400659.","journal-title":"Cell Death Differ"},{"issue":"4678","key":"77_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984, 226 (4678): 1097-9. 10.1126\/science.6093263.","journal-title":"Science"},{"key":"77_CR28","first-page":"1097","volume":"226","author":"A Bakshi","year":"1099","unstructured":"Bakshi A, Jensen JP, Goldman P: Cloning the chromosomal breakpoint of t(14;18) of human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Science. 1099, 226: 1097-1984.","journal-title":"Science"},{"key":"77_CR29","first-page":"25","volume":"18","author":"RJ Klasa","year":"2004","unstructured":"Klasa RJ: Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (Williston Park). 2004, 18: 25-31.","journal-title":"Oncology (Williston Park)"},{"key":"77_CR30","first-page":"6565","volume":"50","author":"JC Reed","year":"1990","unstructured":"Reed JC, Stein C, Subasinghe C: Antisense-mediated inhibition of BCL2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990, 50: 6565-6570.","journal-title":"Cancer Res"},{"issue":"5","key":"77_CR31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2007.15.8022","volume":"26","author":"S O'Brien","year":"2008","unstructured":"O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A: Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2008, 26 (5): 820-","journal-title":"J Clin Oncol"},{"issue":"5689","key":"77_CR32","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1126\/science.1099191","volume":"305","author":"LD Walensky","year":"2004","unstructured":"Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004, 305 (5689): 1466-70. 10.1126\/science.1099191.","journal-title":"Science"},{"issue":"48","key":"77_CR33","doi-asserted-by":"publisher","first-page":"36999","DOI":"10.1074\/jbc.M602341200","volume":"281","author":"KJ Oh","year":"2006","unstructured":"Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD: A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. J Biol Chem. 2006, 281 (48): 36999-7008. 10.1074\/jbc.M602341200.","journal-title":"J Biol Chem"},{"key":"77_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.chembiol.2004.02.020","volume":"11","author":"B Becattini","year":"2004","unstructured":"Becattini B, Kitada S, Leone M: Rational design and real time in-cell detection of the pro-apoptotic activity of a novel compound targeting Bcl-Xl. Chem Biol. 2004, 11: 389-395. 10.1016\/j.chembiol.2004.02.020.","journal-title":"Chem Biol"},{"issue":"3","key":"77_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0010-7824(88)90027-3","volume":"37","author":"M Sonenberg","year":"1988","unstructured":"Sonenberg M, Huang JT, Ren YF, Su TL, Watanabe KA: Anti-fertility and other actions of gossypol analogues. Contraception. 1988, 37 (3): 247-55. 10.1016\/0010-7824(88)90027-3.","journal-title":"Contraception"},{"key":"77_CR36","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","volume":"13","author":"D Zhai","year":"2006","unstructured":"Zhai D, Jin C, Satterthwait AC, Reed JC: Comparison of chemical inhibitors of anti-apoptotic Bcl-2-family proteins. Cell Death Differ. 2006, 13: 1419-1421. 10.1038\/sj.cdd.4401937.","journal-title":"Cell Death Differ"},{"issue":"6","key":"77_CR37","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1182\/blood-2007-09-113647","volume":"111","author":"S Kitada","year":"2008","unstructured":"Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M: Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood. 2008, 111 (6): 3211-3219. 10.1182\/blood-2007-09-113647.","journal-title":"Blood"},{"key":"77_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1476-4598-7-20","volume":"7","author":"AA Arnold","year":"2008","unstructured":"Arnold AA, Aboukameel A, Chen J, Yang D, Wang S: Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer. 2008, 7: 20-10.1186\/1476-4598-7-20.","journal-title":"Mol Cancer"},{"key":"77_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0165-4608(93)90132-6","volume":"70","author":"RM Mohammad","year":"1993","unstructured":"Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993, 70: 62-67. 10.1016\/0165-4608(93)90132-6.","journal-title":"Cancer Genet Cytogenet"},{"issue":"7042","key":"77_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005, 435 (7042): 677-81. 10.1038\/nature03579.","journal-title":"Nature"},{"issue":"5","key":"77_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell. 2006, 10 (5): 389-99. 10.1016\/j.ccr.2006.08.027.","journal-title":"Cancer Cell"},{"issue":"1","key":"77_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ccr.2005.06.012","volume":"8","author":"S Cory","year":"2005","unstructured":"Cory S, Adams JM: Killing cancer cells by flipping the Bcl-2\/Bax switch. Cancer Cell. 2005, 8 (1): 5-6. 10.1016\/j.ccr.2005.06.012.","journal-title":"Cancer Cell"},{"issue":"2","key":"77_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/jm0507532","volume":"49","author":"AM Petros","year":"2006","unstructured":"Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA: Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem. 2006, 49 (2): 656-63. 10.1021\/jm0507532.","journal-title":"J Med Chem"},{"issue":"9","key":"77_CR44","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68 (9): 3421-8. 10.1158\/0008-5472.CAN-07-5836.","journal-title":"Cancer Res"},{"key":"77_CR45","volume-title":"Proceedings AACR","author":"SW Elmore","year":"2007","unstructured":"Elmore SW: ABT 263: an orally available bcl-2 family protein inhibitor. Proceedings AACR. 2007"},{"issue":"11","key":"77_CR46","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","volume":"14","author":"AR Shoemaker","year":"2008","unstructured":"Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M: Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008, 14 (11): 3268-77. 10.1158\/1078-0432.CCR-07-4622.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"77_CR47","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1021\/jm800669s","volume":"51","author":"CM Park","year":"2008","unstructured":"Park CM, Bruncko M, Adickes J, Bauch J, Ding H: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008, 51 (21): 6902-15. 10.1021\/jm800669s. Epub 2008 Oct 8","journal-title":"J Med Chem"},{"issue":"10","key":"77_CR48","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1158\/1535-7163.MCT-08-0268","volume":"7","author":"S Ackler","year":"2008","unstructured":"Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A: ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008, 7 (10): 3265-74. 10.1158\/1535-7163.MCT-08-0268.","journal-title":"Mol Cancer Ther"},{"key":"77_CR49","first-page":"1371","volume":"110","author":"WH Wilson","year":"2007","unstructured":"Wilson WH, Tulpule A, Levine AM: A phase 1\/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with Refractory or Relapsed Lymphoid Malignancies. Blood (ASH Annual Meeting Abstracts). 2007, 110: 1371-","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"13","key":"77_CR50","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.97.13.7124","volume":"97","author":"JL Wang","year":"2000","unstructured":"Wang JL, Liu D, Zhang ZJ, Shan S, Han X: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci. 2000, 97 (13): 7124-7129. 10.1073\/pnas.97.13.7124.","journal-title":"Proc Natl Acad Sci"},{"issue":"5-6","key":"77_CR51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0006-2952(02)01148-6","volume":"64","author":"JB Baell","year":"2002","unstructured":"Baell JB, Huang DCS: Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol. 2002, 64 (5-6): 851-63. 10.1016\/S0006-2952(02)01148-6.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"77_CR52","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.leukres.2005.08.022","volume":"30","author":"J Skommer","year":"2006","unstructured":"Skommer J, Wlodkowic D, M\u00e4tt\u00f6 M, Eray M, Pelkonen J: HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res. 2006, 30 (3): 322-31. 10.1016\/j.leukres.2005.08.022.","journal-title":"Leuk Res"},{"issue":"9","key":"77_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.leukres.2005.11.024","volume":"30","author":"D Wlodkowic","year":"2006","unstructured":"Wlodkowic D, Skommer J, Pelkonen J: Multiparametric analysis of HA14-1-induced apoptosis in follicular lymphoma cells. Leuk Res. 2006, 30 (9): 1187-92. 10.1016\/j.leukres.2005.11.024.","journal-title":"Leuk Res"},{"issue":"12","key":"77_CR54","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.leukres.2007.03.008","volume":"31","author":"D Wlodkowic","year":"2007","unstructured":"Wlodkowic D, Skommer J, Pelkonen J: Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells. Leuk Res. 2007, 31 (12): 1687-700. 10.1016\/j.leukres.2007.03.008.","journal-title":"Leuk Res"},{"issue":"56","key":"77_CR55","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","volume":"22","author":"JS Fridman","year":"2003","unstructured":"Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene. 2003, 22 (56): 9030-40. 10.1038\/sj.onc.1207116.","journal-title":"Oncogene"},{"key":"77_CR56","first-page":"81","volume":"77","author":"P Hainaut","year":"2000","unstructured":"Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77: 81-137. full_text.","journal-title":"Adv Cancer Res"},{"issue":"6810","key":"77_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408 (6810): 307-10. 10.1038\/35042675.","journal-title":"Nature"},{"issue":"17","key":"77_CR58","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","volume":"14","author":"S Shangary","year":"2008","unstructured":"Shangary S, Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008, 14 (17): 5318-24. 10.1158\/1078-0432.CCR-07-5136.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"77_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.critrevonc.2004.07.002","volume":"52","author":"A Feki","year":"2004","unstructured":"Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol. 2004, 52 (2): 103-16. 10.1016\/j.critrevonc.2004.07.002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"77_CR60","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","volume":"69","author":"J Momand","year":"1992","unstructured":"Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992, 69: 1237-45. 10.1016\/0092-8674(92)90644-R.","journal-title":"Cell"},{"key":"77_CR61","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/j.1460-2075.1991.tb07676.x","volume":"10","author":"SS Fakharzadeh","year":"1991","unstructured":"Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991, 10: 1565-69.","journal-title":"EMBO J"},{"key":"77_CR62","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/geno.1993.1058","volume":"15","author":"SS Fakharzadeh","year":"1993","unstructured":"Fakharzadeh SS, Rosenblum-Vos L, Murphy M, Hoffman EK, George DL: Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics. 1993, 15: 283-90. 10.1006\/geno.1993.1058.","journal-title":"Genomics"},{"key":"77_CR63","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/378206a0","volume":"378","author":"SN Jones","year":"1995","unstructured":"Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995, 378: 206-8. 10.1038\/378206a0.","journal-title":"Nature"},{"key":"77_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/378203a0","volume":"378","author":"R Montes de Oca Luna","year":"1995","unstructured":"Montes de Oca Luna R, Wagner DS, Lozano G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995, 378: 203-6. 10.1038\/378203a0.","journal-title":"Nature"},{"key":"77_CR65","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1128\/MCB.23.2.462-473.2003","volume":"23","author":"SM Mendrysa","year":"2003","unstructured":"Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME: mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol. 2003, 23: 462-72. 10.1128\/MCB.23.2.462-473.2003.","journal-title":"Mol Cell Biol"},{"key":"77_CR66","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1126\/science.274.5289.948","volume":"274","author":"PH Kussie","year":"1996","unstructured":"Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996, 274: 948-53. 10.1126\/science.274.5289.948.","journal-title":"Science"},{"key":"77_CR67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/cc.3.4.801","volume":"3","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT: Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle. 2004, 3: 419-21.","journal-title":"Cell Cycle"},{"key":"77_CR68","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1021\/jm051122a","volume":"49","author":"K Ding","year":"2006","unstructured":"Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S: Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006, 49: 3432-35. 10.1021\/jm051122a.","journal-title":"J Med Chem"},{"issue":"10","key":"77_CR69","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1073\/pnas.0708917105","volume":"105","author":"S Shangary","year":"2008","unstructured":"Shangary S, Qin D, McEachern D, Liu M, Miller RS: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 2008, 105 (10): 3933-8. 10.1073\/pnas.0708917105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"77_CR70","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1128\/MCB.23.2.462-473.2003","volume":"23","author":"SM Mendrysa","year":"2003","unstructured":"Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM: mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol. 2003, 23 (2): 462-72. 10.1128\/MCB.23.2.462-473.2003.","journal-title":"Mol Cell Biol"},{"key":"77_CR71","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2006.10.010","volume":"10","author":"I Ringshausen","year":"2006","unstructured":"Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 2006, 10: 501-14. 10.1016\/j.ccr.2006.10.010.","journal-title":"Cancer Cell"},{"key":"77_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","volume":"7","author":"J Adams","year":"2002","unstructured":"Adams J: Development of the proteasome inhibitor PS-341. Oncologist. 2002, 7: 9-16. 10.1634\/theoncologist.7-1-9.","journal-title":"Oncologist"},{"key":"77_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A Ciechanover","year":"1994","unstructured":"Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell. 1994, 79: 13-21. 10.1016\/0092-8674(94)90396-4.","journal-title":"Cell"},{"key":"77_CR74","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0968-0004(97)01122-5","volume":"22","author":"A Varshavsky","year":"1997","unstructured":"Varshavsky A: The ubiquitin system. Trend Biochem Sci. 1997, 22: 383-387. 10.1016\/S0968-0004(97)01122-5.","journal-title":"Trend Biochem Sci"},{"key":"77_CR75","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1021\/bi00497a001","volume":"29","author":"M Orlowski","year":"1990","unstructured":"Orlowski M: The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry. 1990, 29: 10289-10297. 10.1021\/bi00497a001.","journal-title":"Biochemistry"},{"key":"77_CR76","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","volume":"65","author":"O Coux","year":"1996","unstructured":"Coux O, Tanaka K, Goldberg AL: Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996, 65: 801-847. 10.1146\/annurev.bi.65.070196.004101.","journal-title":"Annu Rev Biochem"},{"key":"77_CR77","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/sj.leu.2402417","volume":"16","author":"JB Almond","year":"2002","unstructured":"Almond JB, Cohen GM: The proteasome: A novel target for cancer chemotherapy. Leukemia. 2002, 16: 433-443. 10.1038\/sj.leu.2402417.","journal-title":"Leukemia"},{"key":"77_CR78","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","volume":"5","author":"B An","year":"1998","unstructured":"An B, Goldfarb RH, Siman R: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998, 5: 1062-1075. 10.1038\/sj.cdd.4400436.","journal-title":"Cell Death Differ"},{"key":"77_CR79","first-page":"4342","volume":"58","author":"RZ Orlowski","year":"1998","unstructured":"Orlowski RZ, Eswara JR, Lafond-Walker A: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58: 4342-4348.","journal-title":"Cancer Res"},{"key":"77_CR80","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1081\/CNV-120030218","volume":"22","author":"J Adams","year":"2004","unstructured":"Adams J, Kauffman M: Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest. 2004, 22: 304-11. 10.1081\/CNV-120030218.","journal-title":"Cancer Invest"},{"key":"77_CR81","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1006321828515","volume":"18","author":"J Adams","year":"2000","unstructured":"Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000, 18: 109-21. 10.1023\/A:1006321828515.","journal-title":"Invest New Drugs"},{"key":"77_CR82","doi-asserted-by":"publisher","first-page":"22123","DOI":"10.1074\/jbc.274.32.22123","volume":"274","author":"GN DeMartino","year":"1999","unstructured":"DeMartino GN, Slaughter CA: The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem. 1999, 274: 22123-6. 10.1074\/jbc.274.32.22123.","journal-title":"J Biol Chem"},{"key":"77_CR83","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","volume":"8","author":"AF Kisselev","year":"2001","unstructured":"Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001, 8: 739-58. 10.1016\/S1074-5521(01)00056-4.","journal-title":"Chem Biol"},{"key":"77_CR84","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59: 2615-22.","journal-title":"Cancer Res"},{"key":"77_CR85","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/med.1009","volume":"21","author":"J Myung","year":"2001","unstructured":"Myung J, Kim KB, Crews CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev. 2001, 21: 245-73. 10.1002\/med.1009.","journal-title":"Med Res Rev"},{"key":"77_CR86","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4161\/cbt.4.1.1379","volume":"4","author":"H Matta","year":"2005","unstructured":"Matta H, Chaudhary PM: The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther. 2005, 4: 77-82. 10.4161\/cbt.4.1.1379.","journal-title":"Cancer Biol Ther"},{"key":"77_CR87","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.leu.2403460","volume":"18","author":"J An","year":"2004","unstructured":"An J, Sun Y, Fisher M, Rettig MB: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004, 18: 1699-704. 10.1038\/sj.leu.2403460.","journal-title":"Leukemia"},{"key":"77_CR88","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.V104.11.3294.3294","volume":"104","author":"L Maharaj","year":"2004","unstructured":"Maharaj L, Strauss S, Stec J, Lister T, Joel S: Mantle cell and follicular lymphoma samples demonstrate differeing sensitivity to bortezomib in a primary culture system. Blood. 2004, 104: 900-","journal-title":"Blood"},{"key":"77_CR89","first-page":"465","volume":"98","author":"L Pham","year":"2001","unstructured":"Pham L, Tamayo AT, Lo P, Yoshimura L, Ford R: Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood. 2001, 98: 465-","journal-title":"Blood"},{"key":"77_CR90","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.389.389","volume":"104","author":"A Goy","year":"2004","unstructured":"Goy A, Remache Y, Barkoh B, Jiang Y, Hart S, Gilles F: Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells. Blood. 2004, 104: 389a-90a.","journal-title":"Blood"},{"key":"77_CR91","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Bernstein S, Kahl B, Epner E, Leonard JP, Stadtmauer E, Morgan D, Belt R, Baidas S, Fisher RI: Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J Clin Oncol. 2005, 23: 6563-10.1200\/JCO.2005.03.108.","journal-title":"J Clin Oncol"},{"key":"77_CR92","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V104.11.175.175","volume":"104","author":"O O'Connor","year":"2004","unstructured":"O'Connor O, Wright J, Moskowitz C, MacGregor-Cortelli B, Straus D, Evans A, Winter J, Koc O, Horvath N, Blumel S, Vose J, Schenkein D: A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition. Blood. 2004, 104: 175-","journal-title":"Blood"},{"key":"77_CR93","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005, 23: 667-75. 10.1200\/JCO.2005.03.108.","journal-title":"J Clin Oncol"},{"key":"77_CR94","volume-title":"Blood","author":"SJ Strauss","year":"2004","unstructured":"Strauss SJ, Maharaj L, Stec J, Boral A, Trehu E, Schenkein D, Johnson P, Joel SP, TA L: Phase II clinical study of bortezomib (velcade) in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). Blood. 2004, 104: 10.1182\/blood-2004-04-1311."},{"key":"77_CR95","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.277.5327.818","volume":"277","author":"JP Sheridan","year":"1997","unstructured":"Sheridan JP, Marsters SA, Pitti RM: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997, 277: 818-821. 10.1126\/science.277.5327.818.","journal-title":"Science"},{"key":"77_CR96","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1126\/science.281.5381.1312","volume":"281","author":"NA Thornberry","year":"1998","unstructured":"Thornberry NA, Lazebnik Y: Caspases: Enemies within. Science. 1998, 281: 1312-1316. 10.1126\/science.281.5381.1312.","journal-title":"Science"},{"key":"77_CR97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1359-6349(04)80233-7","volume":"2","author":"W Halpern","year":"2004","unstructured":"Halpern W, Lincoln C, Sharifi A: Variable distribution of TRAIL Receptor 1 in primary human tumor and normal tissues. Eur J Cancer. 2004, 2: 69-","journal-title":"Eur J Cancer"},{"issue":"9","key":"77_CR98","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.175.9.5586","volume":"175","author":"N Zerafa","year":"2005","unstructured":"Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol. 2005, 175 (9): 5586-90.","journal-title":"J Immunol"},{"issue":"10 Pt 1","key":"77_CR99","first-page":"3731","volume":"9","author":"DJ Buchsbaum","year":"2003","unstructured":"Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and\/or radiation therapy in a human breast cancer model. Clin Cancer Res. 2003, 9 (10 Pt 1): 3731-41.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"77_CR100","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1148\/radiol.2483071740","volume":"248","author":"H Kim","year":"2008","unstructured":"Kim H, Morgan DE, Zeng H, Grizzle WE, Warram JM: Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology. 2008, 248 (3): 844-51. 10.1148\/radiol.2483071740.","journal-title":"Radiology"},{"issue":"2","key":"77_CR101","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4049\/jimmunol.181.2.1001","volume":"181","author":"M Travert","year":"2008","unstructured":"Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O: CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008, 181 (2): 1001-11.","journal-title":"J Immunol"},{"issue":"29","key":"77_CR102","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1200\/JCO.2007.14.0996","volume":"25","author":"AW Tolcher","year":"2007","unstructured":"Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007, 25 (29): 4701-10.1200\/JCO.2007.14.0996.","journal-title":"J Clin Oncol"},{"key":"77_CR103","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood.V106.11.146.146","volume":"106","author":"A Younes","year":"2005","unstructured":"Younes A, Vose JM, Zelenetz AD: Results of a Phase 2 trial of HGS-ETR1(agonist human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed\/refractory non-Hodgkin's lymphoma (NHL). Blood. 2005, 106: 146-","journal-title":"Blood"},{"issue":"5","key":"77_CR104","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/cbt.2.5.453","volume":"2","author":"KW Wagner","year":"2003","unstructured":"Wagner KW, King F, Nomoto K, Knee DA, Hampton G, Nasoff M, Deveraux QL: \"Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells\". Cancer Biol Ther. 2003, 2 (5): 534-540.","journal-title":"Cancer Biol Ther."},{"issue":"b","key":"77_CR105","first-page":"495","volume":"6","author":"S Padhye","year":"2008","unstructured":"Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH: From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. Cancer Ther. 2008, 6 (b): 495-510.","journal-title":"Cancer Ther"},{"issue":"2","key":"77_CR106","first-page":"25","volume":"20","author":"A Al-Ali","year":"2008","unstructured":"Al-Ali A, Alkhawajah AA, Randhawa MA, Shaikh NA: Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. J Ayub Med Coll Abbottabad. 2008, 20 (2): 25-7.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"77_CR107","first-page":"107","volume":"22","author":"AM Shoieb","year":"2003","unstructured":"Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK: In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol. 2003, 22: 107-113.","journal-title":"Int J Oncol"},{"key":"77_CR108","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1126\/science.2683079","volume":"246","author":"LH Hartwell","year":"1989","unstructured":"Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science. 1989, 246: 629-634. 10.1126\/science.2683079.","journal-title":"Science"},{"key":"77_CR109","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1126\/science.7997877","volume":"266","author":"LH Hartwell","year":"1994","unstructured":"Hartwell LH, Kastan MB: Cell cycle control and cancer. Science. 1994, 266: 1821-1828. 10.1126\/science.7997877.","journal-title":"Science"},{"key":"77_CR110","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/00001813-200404000-00012","volume":"15","author":"HU Gali-Muhtasib","year":"2004","unstructured":"Gali-Muhtasib HU, bou Kheir WG, Kheir LA, Darwiche N, Crooks PA: Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs. 2004, 15: 389-399. 10.1097\/00001813-200404000-00012.","journal-title":"Anticancer Drugs"},{"key":"77_CR111","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS el-Deiry","year":"1993","unstructured":"el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75: 817-825. 10.1016\/0092-8674(93)90500-P.","journal-title":"Cell"},{"key":"77_CR112","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/352345a0","volume":"352","author":"E Yonish-Rouach","year":"1991","unstructured":"Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991, 352: 345-347. 10.1038\/352345a0.","journal-title":"Nature"},{"key":"77_CR113","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1073\/pnas.89.10.4495","volume":"89","author":"P Shaw","year":"1992","unstructured":"Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 1992, 89: 4495-4499. 10.1073\/pnas.89.10.4495.","journal-title":"Proc Natl Acad Sci USA"},{"key":"77_CR114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1097-2765(00)80002-7","volume":"1","author":"H Hermeking","year":"1997","unstructured":"Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2\/M progression. Mol Cell. 1997, 1: 3-11. 10.1016\/S1097-2765(00)80002-7.","journal-title":"Mol Cell"},{"key":"77_CR115","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","volume":"282","author":"F Bunz","year":"1998","unstructured":"Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998, 282: 1497-1501. 10.1126\/science.282.5393.1497.","journal-title":"Science"},{"key":"77_CR116","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4161\/cbt.6.2.3575","volume":"6","author":"M Roepke","year":"2007","unstructured":"Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, Schneider-Stock R, Gali-Muhtasib H: Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther. 2007, 6: 160-169. 10.4161\/cbt.6.2.3575.","journal-title":"Cancer Biol Ther"},{"key":"77_CR117","first-page":"209","volume":"115","author":"L Yamasaki","year":"2003","unstructured":"Yamasaki L: Role of the RB tumor suppressor in cancer. Cancer Treat Res. 2003, 115: 209-239. full_text.","journal-title":"Cancer Treat Res"},{"key":"77_CR118","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/00001813-200404000-00012","volume":"15","author":"HU Gali-Muhtasib","year":"2004","unstructured":"Gali-Muhtasib HU, bou Kheir WG, Kheir LA, Darwiche N, Crooks PA: Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs. 2004, 15: 389-399. 10.1097\/00001813-200404000-00012.","journal-title":"Anticancer Drugs"},{"key":"77_CR119","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ijc.21205","volume":"117","author":"MA El-Mahdy","year":"2005","unstructured":"El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA: Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer. 2005, 117: 409-417. 10.1002\/ijc.21205.","journal-title":"Int J Cancer"},{"key":"77_CR120","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1158\/0008-5472.CAN-07-1483","volume":"67","author":"AO Kaseb","year":"2007","unstructured":"Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007, 67: 7782-7788. 10.1158\/0008-5472.CAN-07-1483.","journal-title":"Cancer Res"},{"issue":"13","key":"77_CR121","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1055\/s-2008-1074578","volume":"74","author":"BB Aggarwal","year":"2008","unstructured":"Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung BA: Potential of Spice-Derived Phytochemicals for Cancer Prevention. Planta Med. 2008, 74 (13): 1560-9. 10.1055\/s-2008-1074578.","journal-title":"Planta Med"},{"key":"77_CR122","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1541-7786.MCR-07-2088","volume":"6","author":"G Sethi","year":"2008","unstructured":"Sethi G, Ahn KS, Aggarwal BB: Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis. Mol Cancer Res. 2008, 6: 1059-1070. 10.1158\/1541-7786.MCR-07-2088.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"77_CR123","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1541-7786.MCR-07-2088","volume":"6","author":"G Sethi","year":"2008","unstructured":"Sethi G, Ahn KS, Aggarwal BB: Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008, 6 (6): 1059-70. 10.1158\/1541-7786.MCR-07-2088.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"77_CR124","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1477-2574.2009.00059.x","volume":"11","author":"N Chehl","year":"2009","unstructured":"Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA: Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford). 2009, 11 (5): 373-81.","journal-title":"HPB (Oxford)"},{"issue":"13","key":"77_CR125","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1158\/0008-5472.CAN-08-4235","volume":"69","author":"S Banerjee","year":"2009","unstructured":"Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009, 69 (13): 5575-83. 10.1158\/0008-5472.CAN-08-4235.","journal-title":"Cancer Res"},{"issue":"7","key":"77_CR126","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/1535-7163.MCT-08-0124","volume":"7","author":"T Yi","year":"2008","unstructured":"Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, Liu M: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 2008, 7 (7): 1789-96. 10.1158\/1535-7163.MCT-08-0124.","journal-title":"Mol Cancer Ther"},{"key":"77_CR127","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/0008-5472.CAN-08-0884","volume":"68","author":"H Gali-Muhtasib","year":"2008","unstructured":"Gali-Muhtasib H, Kuester D, Mawrin C, Bajbouj K, Diestel A, Ocker M, Habold C, Foltzer-Jourdainne C, Schoenfeld P, Peters B, ab-Assaf M, Pommrich U, Itani W, Lippert H, Roessner A, Schneider-Stock R: Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells. Cancer Res. 2008, 68: 5609-5618. 10.1158\/0008-5472.CAN-08-0884.","journal-title":"Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-2-50.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T08:14:00Z","timestamp":1630484040000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-2-50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-2-50","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"20 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"50"}}